Waters Corporation
WAT
$368.98
-2.44%
Waters Corporation provides analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools, serving the healthcare and life sciences industries. It is a niche leader in precision analytical instrumentation, known for its high-margin consumables and service business. In early 2026, Waters merged with BD's life science and diagnostics business, significantly expanding its diagnostics and discovery-related tools, which has become the central investor narrative as the market assesses the integration and growth potential of the combined entity.…
WAT
Waters Corporation
$368.98
WAT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $413.13 and implied upside of +12.0% versus the current price.
Average Target
$413.13
0 analysts
Implied Upside
+12.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$349 - $460
Analyst target range
WAT is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating 1.84 on a 1-5 scale, where 1 is Strong Buy). The average target price is $413.13, implying 11.9% upside from the current price of $368.98. The distribution shows 10 Buy/Overweight ratings, 4 Hold/Neutral, and no Sell ratings, indicating a bullish consensus. The target range spans from a low of $349.00 to a high of $460.00. The low target implies a 5.4% downside, while the high target suggests 24.7% upside, reflecting moderate conviction. Recent ratings from Goldman Sachs (Buy), Morgan Stanley (Equal Weight), and Guggenheim (Buy) show stability, with no downgrades. The wide spread between low and high ($111) indicates uncertainty around the BD merger integration and future growth trajectory, but the overall sentiment remains positive.
Drowning in data?
Find the real signal!
Bulls vs Bears: WAT Investment Factors
WAT presents a compelling but high-risk opportunity. The bullish case rests on the transformative BD merger, which has already boosted revenue 91% and positions the company in faster-growing diagnostics. Analysts are broadly optimistic, with 11.9% average upside and no sell ratings. However, the bear case is equally strong: the company is currently unprofitable, gross margins have compressed by 13 percentage points, and organic growth is unclear. The key tension is whether the merger integration will restore margins to pre-merger levels (30%+ operating margin) within 12-18 months. If successful, the stock could re-rate higher; if not, the current valuation premium could unwind. Overall, the evidence slightly favors the bulls given the strategic rationale and analyst support, but execution risk is substantial.
Bullish
- Revenue Surge from BD Merger: Revenue jumped 91.48% YoY to $1.267 billion in Q1 2026, driven by the BD life science acquisition. This dramatically expands the company's scale and diversifies into diagnostics, a high-growth end market.
- Strong Analyst Consensus and Upside: 24 analysts rate WAT a Buy (mean 1.84/5) with an average target of $413.13, implying 11.9% upside from $368.98. The high target of $460 suggests 24.7% potential, reflecting confidence in the merger thesis.
- Attractive Valuation vs. Peers: The trailing P/S ratio of 7.14x is below the industry average of 9.5x, a ~25% discount. Despite merger-related earnings disruption, the forward P/E of 22.37x is reasonable for a company with strong competitive moats.
- Historical Profitability and Cash Flow: Pre-merger, WAT consistently delivered operating margins above 30% (33.3% in Q4 2025) and ROE of 25.1%. TTM free cash flow of $264 million underscores underlying cash generation despite Q1 2026's negative FCF.
Bearish
- GAAP Loss and Margin Compression: Q1 2026 net loss of -$72 million and gross margin collapse to 46.96% from 59.79% in Q4 2025 highlight severe integration costs. Operating margin turned negative -3.71%, raising concerns about near-term profitability.
- Uncertain Organic Growth Trajectory: The 91.48% revenue growth is entirely merger-driven; organic growth is obscured. Pre-merger organic growth was modest (6-8% YoY), and the combined entity's ability to sustain above-market growth is unproven.
- Elevated Valuation on Normalized Earnings: The trailing P/E of 35.17x is near the high end of its 2-year range (22x-49x). The forward P/E of 22.37x assumes a rapid earnings recovery, which may be optimistic if integration challenges persist.
- High Debt and Integration Risk: Debt-to-equity of 0.58 is manageable but elevated post-merger. The BD acquisition adds complexity; any missteps in cost synergies or revenue retention could pressure margins and delay profitability.
WAT Technical Analysis
WAT is in a sustained uptrend over the past year, with a 1-year price change of +24.27%, significantly outperforming the S&P 500's +18.35%. The current price of $368.98 sits at 58.5% of its 52-week range ($275.05–$414.15), indicating room to run but not overextended. The stock is trading above its 52-week low by 34.1%, suggesting a recovery from earlier lows but still below the highs, reflecting cautious optimism. Short-term momentum is positive, with a 1-month change of +3.36% and a 3-month change of +12.57%, both outpacing the S&P 500's 0.31% and 4.67% respectively. This acceleration in momentum over the past three months contrasts with a 6-month decline of -4.75%, suggesting a potential trend reversal from the earlier pullback. The relative strength index (RSI) is not provided, but the volume of 573,587 shares is moderate, indicating steady interest. The 52-week low of $275.05 provides strong support, while the 52-week high of $414.15 is the key resistance level. A breakout above $414.15 would signal a resumption of the long-term uptrend, while a breakdown below $275.05 would be a bearish signal. With a beta of 1.202, WAT is 20.2% more volatile than the market, meaning it amplifies market moves, which is important for risk management.
Beta
1.20
1.20x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
+24.3%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | -0.5% |
| 3m | +12.6% | +4.9% |
| 6m | -4.7% | +9.7% |
| 1y | +24.3% | +18.4% |
| ytd | -3.4% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Revenue surged 91.48% year-over-year in the most recent quarter (Q1 2026) to $1.267 billion, driven by the BD merger, though organic growth is obscured. Prior to the merger, revenue was growing steadily: Q4 2025 revenue was $932.4 million (up 6.8% YoY from Q4 2024's $872.7 million), and Q3 2025 revenue was $799.9 million (up 8.0% YoY). The merger has dramatically boosted top-line, but the underlying organic growth rate is likely lower. The company is currently unprofitable on a GAAP basis, reporting a net loss of -$72 million in Q1 2026, compared to net income of $225.2 million in Q4 2025. Gross margin compressed to 46.96% in Q1 2026 from 59.79% in Q4 2025, likely due to merger-related costs and integration expenses. Operating margin turned negative at -3.71% in Q1 2026, versus 33.31% in Q4 2025. The company has a debt-to-equity ratio of 0.58, which is manageable, and a current ratio of 1.73, indicating adequate liquidity. Free cash flow was negative -$42 million in Q1 2026, but trailing twelve-month free cash flow is $264 million, showing underlying cash generation. ROE is 25.1%, reflecting strong profitability on a normalized basis, though the recent loss distorts this metric.
Quarterly Revenue
$1.3B
2026-04
Revenue YoY Growth
+91.5%
YoY Comparison
Gross Margin
47.0%
Latest Quarter
Free Cash Flow
$263999000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Since net income is negative in the most recent quarter, the trailing P/E is not meaningful; we use the P/S ratio of 7.14x (trailing) and forward P/E of 22.37x. The forward P/E suggests the market expects a return to profitability, with the gap between trailing and forward implying significant earnings recovery. The P/S ratio of 7.14x is below the industry average of 9.5x (estimated), indicating a discount of about 25%. However, the forward P/E of 22.37x is at a premium to the sector median of 18x, reflecting expectations of above-average growth post-merger. Historically, WAT's trailing P/E has ranged from 22x to 49x over the past two years. The current trailing P/E of 35.17x (based on last four quarters' net income) is near the middle of that range, suggesting the stock is fairly valued relative to its own history. The P/B ratio of 8.83x is elevated but consistent with historical levels, reflecting the company's asset-light model and high returns on equity.
PE
35.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 22x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The most immediate risk is the GAAP net loss of -$72 million in Q1 2026, driven by integration costs and margin compression. Gross margin fell from 59.79% to 46.96%, and operating margin turned negative at -3.71%. The company's free cash flow turned negative -$42 million in Q1, though TTM FCF remains positive at $264 million. The elevated debt-to-equity of 0.58 increases financial leverage, and any delay in achieving cost synergies could prolong the earnings drag. Revenue concentration risk is moderate, as the BD acquisition adds diagnostics exposure, but the combined entity still relies heavily on life sciences capital spending cycles.
Market & Competitive Risks: WAT's beta of 1.202 makes it 20% more volatile than the market, amplifying downside in a downturn. The forward P/E of 22.37x is a premium to the sector median of 18x, leaving it vulnerable to multiple compression if growth disappoints. The diagnostics market is competitive, with players like Danaher and Thermo Fisher, and the BD integration may distract from innovation. Regulatory risks include FDA oversight of diagnostic products and potential changes in healthcare funding. The stock's 52-week range ($275-$414) shows significant volatility, and the current price is only 11% above the low target of $349, implying limited downside protection.
Worst-Case Scenario: If the merger integration fails to deliver expected synergies, margins remain depressed, and organic growth stalls, the stock could fall to the 52-week low of $275.05, representing a -25.5% decline from the current price of $368.98. This scenario would likely involve multiple quarters of losses, analyst downgrades, and a re-rating to a lower P/E multiple. The historical max drawdown of -31.32% suggests a potential loss of up to $115 per share, bringing the price to around $253, which is below the 52-week low. In this adverse case, an investor could lose approximately 25-31% of their investment.
